Gene · 4261
Papers3,496
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,496
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. | Cancer Cell | 2024 | 38278149 | PubTator, text mining | PubMed |
| Re-centauring T cell antigen discovery around CD4+ T cells. | Cell Rep Methods | 2024 | 38262348 | PubTator, text mining | PubMed |
| Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells. | Biomedicines | 2024 | 38255224 | PubTator, text mining | PubMed |
| Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit. | Cancers (Basel) | 2024 | 38254801 | PubTator, text mining | PubMed |
| Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease. | Biomolecules | 2024 | 38254673 | PubTator, text mining | PubMed |
| Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? | Cells | 2024 | 38247837 | PubTator, text mining | PubMed |
| Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma. | EBioMedicine | 2024 | 38244291 | PubTator, text mining | PubMed |
| Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. | Nat Commun | 2024 | 38225288 | PubTator, text mining | PubMed |
| Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers. | Stem Cell Reports | 2024 | 38215755 | PubTator, text mining | PubMed |
| Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases. | Acta Neuropathol | 2024 | 38214778 | PubTator, text mining | PubMed |
| NLRP3 regulates CIITA/MHC II axis and interferon-γ-inducible chemokines in Malassezia globosa-infected keratinocytes. | Mycoses | 2024 | 38214420 | PubTator, text mining | PubMed |
| Cultures of Human Skin Mast Cells, an Attractive In Vitro Model for Studies of Human Mast Cell Biology. | Cells | 2024 | 38201301 | PubTator, text mining | PubMed |
| Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs? | J Transl Med | 2024 | 38195462 | PubTator, text mining | PubMed |
| LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1/SOCS1 and STAT1/CIITA pathways to promote the progression of non-small cell lung cancer. | Cell Signal | 2024 | 38168631 | PubTator, text mining | PubMed |
| Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine. | EBioMedicine | 2024 | 38160529 | PubTator, text mining | PubMed |
| Identification of AP002498.1 and LINC01871 as prognostic biomarkers and therapeutic targets for distant metastasis of colorectal adenocarcinoma. | Cancer Med | 2024 | 38083905 | PubTator, text mining | PubMed |
| The intrinsically disordered transcriptional activation domain of CIITA is functionally tuneable by single substitutions: An exception or a new paradigm? | Protein Sci | 2024 | 38073129 | PubTator, text mining | PubMed |
| Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review. | Biomed J | 2024 | 37940045 | PubTator, text mining | PubMed |
| Interactome analysis implicates class II transactivator (CIITA) in depression and other neuroinflammatory disorders. | Int J Neurosci | 2024 | 37933915 | PubTator, text mining | PubMed |
| Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments. | Cancer Immunol Res | 2024 | 37922365 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4261/papers?page=10